You are viewing: India Nuclear Medicine Market analysis
Part of: Nuclear Medicine Market (Global)

The India Nuclear Medicine Market was valued at $276.7 Million in 2025 and projected to reach to $643.4 Million by 2030, representing a compound annual growth rate of 18.4%. India's nuclear medicine market is poised for exceptional growth through 2030, driven by escalating disease prevalence, improved diagnostic capabilities, and expanding healthcare accessibility.

India Nuclear Medicine Market (2025-2030) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

India Nuclear Medicine Market Trends and Insights

  • This represents an 18.4% compound annual growth rate, significantly outpacing global trends.
  • India's growth is driven by increasing prevalence of cancer and cardiovascular diseases, rising healthcare infrastructure investments, and growing adoption of diagnostic imaging technologies across urban and emerging tier-2 cities. The Indian nuclear medicine sector benefits from government initiatives promoting advanced diagnostic capabilities and a large patient population requiring early disease detection.
  • India's expanding middle class and improved reimbursement policies are accelerating demand for PET-CT and SPECT imaging services.
  • By 2030, India is expected to establish itself as a key regional hub for nuclear medicine, supported by skilled radiologists, cost-competitive services, and increasing awareness among healthcare providers and patients regarding the clinical benefits of nuclear diagnostic procedures..

Key Market Statistics

  • CAGR (2025-2030) 18.4% CAGR
  • Market Size, 2025 ~USD 276.7 Million
  • Forecast, 2030 ~USD 643.4 Million
  • Country India

India Nuclear Medicine Market Overview

Fastest Growing Market Globally :

India's nuclear medicine market is expanding at 18.4% CAGR, significantly outpacing the global growth rate of 15.1%, positioning it as one of the most dynamic healthcare segments in the region.

Disease Burden Driving Demand :

Rising prevalence of cancer and cardiovascular diseases in India is creating substantial demand for diagnostic and therapeutic nuclear medicine procedures, with patient volumes expected to surge through 2030.

Healthcare Infrastructure Investment :

Government initiatives and private sector investments in nuclear medicine facilities, PET-CT centers, and radiopharmaceutical production are expanding accessibility across urban and emerging markets in India.

Market Valuation Growth :

The Indian market is projected to more than double from USD 276.7 million in 2025 to USD 643.4 million by 2030, reflecting strong adoption and commercialization of nuclear medicine technologies.

India Nuclear Medicine Market Dynamics

  • The 18.4% CAGR reflects increasing adoption of PET-CT imaging, radiopharmaceutical therapies, and nuclear cardiology procedures across metropolitan and tier-2 cities.
  • Government support for nuclear medicine infrastructure and rising healthcare spending among middle-class populations are accelerating market penetration. The forecast trajectory to USD 643.4 million by 2030 underscores India's emergence as a critical market for nuclear medicine stakeholders.
  • Regulatory improvements, growing medical professional expertise, and cost-effective treatment options position India as an attractive investment destination.
  • Continued expansion of diagnostic centers and therapeutic applications will sustain double-digit growth, making India a key growth engine for the global nuclear medicine industry..

Related Ecosystem

Pharmaceuticals

Top Technologies
  • Bioreactors
  • Analytical Testing
  • Bioanalytical Testing Services
  • Cell Counters
  • Data Management Services
Top Companies
  • Merck KGaA
  • Thermo Fisher Scientific Inc.
  • SANOFI
  • NOVARTIS
  • Pfizer Inc.

    Key Takeaways

    • India's nuclear medicine market will nearly double from USD 276.7M (2025) to USD 643.4M (2030), driven by 18.4% CAGR
    • Rising cancer and cardiovascular disease prevalence in India is accelerating demand for advanced diagnostic imaging modalities
    • India's cost-competitive nuclear medicine services position the country as an emerging regional hub for diagnostic imaging
    • Government healthcare initiatives and improved reimbursement policies in India are expanding patient access to nuclear medicine procedures

    Nuclear Medicine Market Report Scope

    Report Metric Details
    Base Year 2025
    Fastest Growing Segment THERAPEUTIC NUCLEAR MEDICINE (Type)
    Forecast Period 2025–2030
    Growth Rate CAGR of 15.1% from 2025 to 2030
    Largest Segment DIAGNOSTIC NUCLEAR MEDICINE (Type)
    Market Size Base Year (Billions) ~USD 10.4 (2025)
    Revenue Forecast (Billions) ~USD 21.01 (2030)
    Segments Covered Type

    India Nuclear Medicine Market Report Segmentation

    1 segment dimensions are covered across the global market.

    By Type

    • Alpha Emitters
    • Beta Emitters
    • Brachytherapy Isotopes
    • Diagnostic Nuclear Medicine
    • F-18
    • Ga-67
    • I-123
    • I-131
    • Lu-177
    • Other Beta Emitters
    • Other Pet Radiopharmaceuticals
    • Other Spect Radiopharmaceuticals
    • Pet Radiopharmaceuticals
    • Ra-223
    • Rb-82
    • Sm-153
    • Spect Radiopharmaceuticals
    • Tc-99M
    • Therapeutic Nuclear Medicine
    • Tl-201
    • Y-90

    INDIA: NUCLEAR MEDICINE MARKET, BY END USER, 2023–2030

    Segment20232024202520262027202820292030CAGR (%)
    ACADEMIC & RESEARCH INSTITUTES1922.326.330.936.442.850.35917.6
    DIAGNOSTIC & IMAGING CENTERS53.56476.691.7109.7131.3156.9187.319.6
    HOSPITALS119.1140.6166.1196.3231.8273.7322.9380.418
    OTHER END USERS5.66.57.68.910.412.214.316.717
    TOTAL197.2233.5276.7327.9388.4459.9544.3643.418.4

    Target Audience

    • Medical Device Manufacturers : Manufacturers of PET-CT scanners, gamma cameras, and nuclear imaging equipment need India-specific market data to identify expansion opportunities, assess competitive landscape, and plan localized manufacturing strategies.
    • Radiopharmaceutical Companies : Producers and distributors of radiopharmaceuticals require detailed India market insights to understand demand patterns, regulatory requirements, and growth opportunities in diagnostic and therapeutic applications.
    • Healthcare Facility Operators : Hospital chains and diagnostic centers planning nuclear medicine service expansion need market forecasts and infrastructure data to justify capital investments and optimize facility development in India.
    • Investment & Private Equity Firms : Investors evaluating healthcare opportunities in India require comprehensive market analysis, growth projections, and competitive dynamics to make informed investment decisions in nuclear medicine ventures.
    • Healthcare Policy & Government Bodies : Government agencies and healthcare planners need India market data to develop nuclear medicine infrastructure policies, allocate resources effectively, and support healthcare accessibility initiatives across regions.

    Reasons to Buy this Report

    • Quantified Market Opportunity : Access precise market sizing data showing India's nuclear medicine market growing from USD 276.7M to USD 643.4M by 2030, enabling accurate revenue projections and investment planning for the Indian healthcare sector.
    • Competitive Intelligence : Understand India-specific market dynamics, competitive positioning, and growth drivers that differentiate this market from global trends, allowing strategic market entry and expansion planning.
    • Investment Decision Support : Leverage detailed India market analysis to identify high-growth segments, facility expansion opportunities, and technology adoption trends critical for capital allocation and partnership decisions.
    • Regulatory & Infrastructure Insights : Gain actionable intelligence on India's healthcare infrastructure development, government initiatives, and regulatory environment shaping nuclear medicine adoption and commercialization pathways.
    • Risk Mitigation & Forecasting : Utilize India-specific CAGR projections and market forecasts to develop robust business strategies, mitigate market entry risks, and align product development with localized demand patterns.

    Frequently asked questions

    What is the current size of India's nuclear medicine market?

    India's nuclear medicine market is valued at USD 276.7 million in 2025 and is projected to grow to USD 643.4 million by 2030.

    What is the expected growth rate for India's nuclear medicine market?

    India's nuclear medicine market is expected to grow at a compound annual growth rate (CAGR) of 18.4% from 2025 to 2030.

    What are the primary drivers of growth in India's nuclear medicine market?

    Key growth drivers in India include rising prevalence of cancer and cardiovascular diseases, expanding healthcare infrastructure, government initiatives, improved reimbursement policies, and increasing adoption of PET-CT and SPECT imaging technologies.

    How does India's nuclear medicine market growth compare to global trends?

    India's 18.4% CAGR significantly outpaces the global nuclear medicine market CAGR of 15.1%, positioning India as a high-growth market within the Asia Pacific region.

    What factors make India attractive for nuclear medicine expansion?

    India offers a large patient population, cost-competitive services, skilled radiologists, expanding middle class, improving healthcare infrastructure, and government support for advanced diagnostic capabilities.

    RESEARCH METHODOLOGY

    This study involved four major activities in estimating the size of the nuclear medicine market. Exhaustive secondary research was done to collect information on the market, peer market, and parent market. The next step was to validate these findings, assumptions, and sizing with industry experts across value chains through primary research. The bottom-up approach was employed to estimate the overall market size. After that, market breakdown and data triangulation were used to estimate the market size of segments and sub-segments.

    Secondary Research

    The secondary research process involved the widespread use of secondary sources, directories, databases (such as Bloomberg Businessweek, Factiva, and D&B Hoovers), white papers, annual reports, company house documents, investor presentations, and SEC filings of companies. Some non-exclusive secondary sources include the Organisation for Economic Co-operation and Development (OECD), European Association of Nuclear Medicine (EANM), National Institutes of Health (NIH), World Nuclear Association (WNA), International Atomic Energy Agency (IAEA), Nuclear Regulatory Commission (NRC), Society of Nuclear Medicine and Molecular Imaging (SNMMI), Nuclear Energy Agency (NEA), Australian Nuclear Science and Technology Organisation (ANSTO), Annual Reports, SEC Filings, Investor Presentations, Journals, Publications from Government Sources and Professional Associations, Expert Interviews, and MarketsandMarkets Analysis.

    Secondary research was used to identify and collect information useful for the extensive, technical, market-oriented, and commercial study of the clinical decision support system market. It was also used to obtain important information about the key players and market classification and segmentation according to industry trends to the bottom-most level, and key developments related to market and technology perspectives. A database of the key industry leaders was also prepared using secondary research.

    Primary Research

    In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side include industry experts such as CEOs, vice presidents, marketing and sales directors, technology & innovation directors, and related key executives from various key companies and organizations operating in the clinical decision support system market. The primary sources from the demand side included industry experts, consultants, healthcare providers, hospital administration, and government bodies. Primary research was conducted to validate the market segmentation, identify key players in the market, and gather insights on key industry trends and key market dynamics.

    Breakdown of Primary Interviews

    Nuclear Medicine Market Size, and Share

    Note 1: Others include sales managers, marketing managers, business development managers, product managers, distributors, and suppliers.

    Note 2: Tiers of companies are defined on the basis of their total revenue in 2022; Tier 1: >USD 1 billion, Tier 2: USD 500 million to USD 1 billion, and Tier 3: <USD 500 million.

    To know about the assumptions considered for the study, download the pdf brochure

    Report Metric

    Details

    Siemens Healthineers

    Sr.Sales Manager

    Curium

    General Manager

    Cardinal Health

    Product Sales Specialist

    Market Size Estimation

    Both top-down and bottom-up approaches were used to estimate and validate the total size of the nuclear medicine market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

    • The key players in the industry and markets have been identified through extensive secondary research
    • The industry’s supply chain and market size, in terms of value, have been determined through primary and secondary research processes
    • All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources

    Data Triangulation

    After arriving at the overall market size—using the market size estimation processes as explained above—the market was split into several segments and sub-segments. To complete the overall market engineering process and arrive at the exact statistics of each market segment and subsegment, the data triangulation, and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides, in the provider, payer, and other industries.

    Market Definition

    Radiopharmaceuticals are drugs that contain radionuclide-emitting ionizing radiation and are used in nuclear imaging to diagnose and treat diseases. The nuclear medicine market is bifurcated into diagnostic and therapeutic segments. Radiopharmaceuticals in the diagnostics market are categorized as SPECT and PET, while radiopharmaceuticals in the therapeutics market are categorized as beta emitters, alpha emitters, and brachytherapy isotopes.

    Key Stakeholders

    • Senior Management
    • Finance/Procurement Department
    • R&D Department

    Report Objectives

    • To define, describe, and forecast the nuclear medicine market on the basis of type, application, procedure volume,end user, and region
    • To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
    • To strategically analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall market
    • To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
    • To forecast the size of the market segments with respect to four main regions—North America, Europe, the Asia Pacific, and the Rest of the World (RoW)
    • To profile the key players and comprehensively analyze their market shares and core competencies
    • To track and analyze competitive developments such as partnerships, collaborations, agreements, product approval & enhancements, expansions, and acquisitions in the nuclear medicine market

    Available Customizations

    MarketsandMarkets offers the following customizations for this market report:

    • Additional country-level analysis of the nuclear medicine market.
    • Profiling of additional market players (up to 3)

    Get the Full Nuclear Medicine Market Report

    Full forecast, segment splits, and company analysis for all Nuclear Medicine Market.

    Need a Tailored Report?

    Customize this report to your needs

    Get 10% FREE Customization

    Customize This Report
    Fact checked
    DMCA.com Protection Status